Entrepreneur-in-Residence Team

Dr. Diane M. Ignar is a distinguished pharmaceutical executive and strategic advisor with over 25 years of comprehensive experience spanning the complete biopharmaceutical value chain from discovery research through commercialization. Her extensive expertise encompasses therapeutic development, business partnerships, emerging markets strategy, and technology innovation across multiple therapeutic areas including neuropharmacology, metabolic diseases, respiratory and allergic diseases, rare diseases, and oncology.

Jonathan B. Kay, MPP, is an Executive-in-Residence (EIR) at BioHealth Innovation, where he provides strategic technical assistance to biotech and life sciences startups to advance technological innovation and drive high-value job creation in the regional ecosystem. As a trusted advisor to the life sciences industry, he brings comprehensive expertise across biotech, pharmaceuticals, medical devices, diagnostics, vaccines, and digital health, including artificial intelligence applications in healthcare.

Douglas Liu is a distinguished business leader and operations executive with over 40 years of comprehensive experience in the biotechnology industry, specializing in manufacturing, quality assurance, regulatory affairs, and global operations management. His career spans the complete biotechnology value chain from early-stage development through commercial manufacturing, with particular expertise in molecular diagnostics, clinical research, and international business development.

Victoria Manax Rutson M.D. is a medical oncologist with over two decades of expertise in the pharmaceutical/biotech industry with a focus on global drug/device/diagnostic development, nanomedicines, novel immunotherapies, and product launch/commercialization.  Dr. Manax has made indelible contributions to the field with her expertise in shaping clinical trial landscapes, particularly in adaptive platform designs with biomarker integration from Phase I-IV.   She has most recently joined Eckuity Capital as a partner. Dr. Manax has played a pivotal role in the development, approval, and launch of billion-dollar products, including the standards of care for breast cancer, lung cancer, and most recently, pancreatic cancer.  She has held multiple executive medical positions in companies including Abraxis Bioscience and Celgene (BMS).  In addition to her pharmaceutical expertise, she was the inaugural Chief Medical Officer for the Pancreatic Cancer Action Network. She has effectively overseen numerous multimillion-dollar global clinical trial programs, holds multiple clinical advisories, chair positions, and patents, exemplifying her commitment to advancing medical science and patient well-being. She is an internationally recognized speaker from programs through Harvard Business School and is a proud Belfast Ambassador recipient. Dr. Manax has received multiple distinguished honors including Who’s Who in Healthcare and was recently named as a government advisor to Northern Ireland for Health and Life Sciences.

Dr. Albine Martin is a seasoned C-level executive with over three decades of experience translating innovation from laboratory to clinic. She currently serves as an Executive in Residence, where she focuses on triaging innovations and intellectual property portfolios toward company formation strategies while supporting the regional startup ecosystem. Dr. Martin earned her Ph.D. in Biochemistry from the University of Maryland, College Park, with a thesis on the biochemistry of lipid-linked pathways in oligosaccharide-linked protein pathways. She also holds a B.S. from Trinity College, Washington, DC, and has completed executive education programs at Cornell University (Certificate in Financial Management) and Harvard Business School (Leadership & Strategy Program in Pharmaceutical and Biotechnology).

Dr. Kimberly E. Martin is a distinguished scientific and clinical affairs executive with over 25 years of comprehensive experience bringing drugs and medical devices to market. As an Entrepreneur-in-Residence (EIR) and advisor to the National Institutes of Health (NIH), she combines deep technical expertise in clinical trial design and regulatory strategy with innovative leadership in pharmaceutical and medical device development across multiple therapeutic areas.

Chris Mathia is a proven medical device and digital health executive with a distinguished track record of leading turnaround efforts and delivering exceptional shareholder value. Based in Olathe, Kansas, he brings over two decades of healthcare technology leadership experience, specializing in acquisition-proven CEO tenures with deep roots in sales leadership. Chris earned his Bachelor of Arts in Political Science from the University of Kansas and built his career foundation through progressive sales roles at leading medical device companies including Medline Industries, Aesculap/B.Braun, and Specialty Medical Systems before transitioning into healthcare technology leadership. His most notable achievement came as CEO of Innara Health, where he led the organization through a comprehensive reorganization and recapitalization process that culminated in a successful acquisition by Cardinal Health, a Fortune 15 organization, in February 2023. Innara Health's NTrainer solution holds the distinction of being the only FDA-cleared medical device clinically proven to improve feeding outcomes for newborns and infants born prematurely.

Quan Nguyen is a Partner at Nguyen Tarbet Intellectual Property Law, representing inventors and organizations with impactful, cutting-edge technologies. Quan has a great passion for the process of commercializing new inventions. He works closely with his clients to build winning patent portfolios and helps identify strategic partners, screen for potential business deals, and analyze market opportunities. Quan is also an active member of the Tech Coast Angels (TCA), Desert Angels, and Life Science Angels, where he leads a number of investment deals. As a seasoned patent attorney, Quan concentrates his practice in patent procurement, opinion work (patentability and freedom to operate analysis), and intellectual property management of inventions in biotechnology, chemistry, medical devices, microfluidics, bioinformatics, and artificial intelligence. His clients include publicly traded companies, major corporations, universities, investors, and entrepreneurs. Prior to founding Nguyen Tarbet LLC, Quan was a Partner at Cozen O’Connor, an international law firm based in Philadelphia. Earlier in his career, Quan also worked in-house as an Assistant Director of Patents at Ionis Pharmaceuticals in San Diego, a leader in RNA-targeted therapeutics. Quan firmly believes in public service and works tirelessly to advance innovation and entrepreneurship. He is an active Member of the College of Science Dean’s Board of Advisors (University of Arizona), School of Pharmacy and Pharmaceutical Sciences Dean's Leadership Council (University of California, Irvine) and Beall Applied Innovation (University of California Irvine), where he leads various university initiatives to promote innovation through industry partnerships. As Chairman Emeritus of the Advisory Board of the Chemistry and BioChemistry Board of Advisors (University of Arizona), he helped the department develop strategic industry relationships to advance faculty research. Quan regularly speaks at seminars about innovation, technology investments, and trends in patent law.

Dr. Kuldeep Neote is a seasoned biotechnology executive and venture capital professional with over 25 years of experience in external innovation, business development, and strategic partnerships across the life sciences industry. His career encompasses roles at leading pharmaceutical companies, innovative biotech ventures, and investment organizations, with particular expertise in immunology, oncology, and gene therapy development.

Caroline is a business leader, physician, and lawyer with more than 30 years of experience across medical technology, diagnostics, life sciences, commercialization strategy, and healthcare innovation. With training as an internist and pathologist, she brings a rare combination of clinical insight, business leadership, legal perspective, and market strategy to her work with emerging companies and technology-enabled healthcare organizations. Caroline has advised and built healthcare, diagnostics, and life science tools companies from early financing through exit, supporting team formation, facility development, intellectual property strategy, financing, partnership development, regulatory planning, and commercialization. She works with founders and leadership teams to evaluate technologies in the context of clinical need, market dynamics, policy shifts, competitive trends, and global commercialization opportunities. Her experience includes operational and strategic roles at BD, where she helped create the BD QIAGEN joint venture and molecular diagnostics business unit, as well as leadership roles at bioMérieux and MDS Proteomics. She later founded Popper and Company, a strategy consulting firm, and co-founded The Sherpanis with Julie Wilkinson. Caroline has also served as Chief Commercial Officer of Johns Hopkins Precision Medicine, where she worked closely with clinicians, data scientists, and collaborators on issues related to privacy, cloud storage, data federation, and commercialization. She also led commercialization activities for the Johns Hopkins Applied Physics Lab Healthcare Mission Area. Her expertise spans technology assessment, commercialization strategy, global market development, data strategy, privacy, compliance, corporate governance, regulatory considerations, and the translation of academic innovation into market-ready products and services. She currently serves as co-chair of the American Bar Association Healthcare Section AI Task Force, reflecting her continued focus on the intersection of healthcare, biology, technology, and artificial intelligence.

Deanne Randolph has a long record of success in strategic marketing for leading biotech, pharmaceutical, and consumer-driven healthcare brands. From early development through launch, Deanne has led multiple US, European, and global initiatives along with several major pharmaceutical and biotechnology product launches. Deanne’s ability to integrate professional, payer, and patient needs to identify growth-driving market strategies is particularly relevant in today’s competitive healthcare environment. She provides Sante Group clients expertise in strategic pre-launch planning, positioning, and targeting; life cycle management and clinical development strategy; global branding; medical education; and direct-to-consumer marketing. Deanne has worked in both primary and secondary care across a broad range of therapeutic areas including immunology, oncology, rheumatology, neurology, pain and rare diseases. Prior to consulting, Deanne held brand management and commercial development positions at Pfizer, Johnson & Johnson, and Bayer. She holds both an MBA and a BA from Wake Forest University.

John P. Reinhart is an accomplished C-suite executive and serial entrepreneur who specializes in Longevity Economy innovation, with nearly two decades of recognition for transformative contributions to healthcare and aging services. As a visionary leader in the intersection of technology, healthcare, and demographic change, he has co-founded multiple ventures and led organizations that address the evolving needs of America's aging population while creating scalable business solutions.